Skip to main content

Postpartum Hemorrhage

7
Pipeline Programs
12
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 12 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
MisoprostolPhase 3
Cipla
CiplaIndia - Mumbai
1 program
1
MisoprostolPhase 31 trial
Active Trials
NCT01373359Completed652Est. Jan 2008
Cipla USA
Cipla USANJ - Warren
1 program
1
MisoprostolPhase 3
Grand Medical
Grand MedicalIsrael - Ramat Gan
1 program
1
TampostatPhase 1/2Small Molecule1 trial
Active Trials
NCT02416089Terminated344Est. Dec 2016
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
fibrinogen concentratePhase 1/2
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
IH OxytocinPhase 1
IM oxytocin 10 IUPhase 1
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
Fibrinogen Concentrate HumanN/A1 trial
Active Trials
NCT03784794Completed100Est. Dec 2020
KoKo
KoKoGA - Atlanta
1 program
KOKO DeviceN/A1 trial
Active Trials
NCT06452355Recruiting72Est. Aug 2026
Lundbeck
LundbeckDenmark - Copenhagen
1 program
Safe Delivery smartphone applicationN/A1 trial
Active Trials
NCT02185625Completed3,773Est. Sep 2014
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
CarbetocinPHASE_11 trial
Active Trials
NCT05924321Completed40Est. Sep 2023
GSK
GSKLONDON, United Kingdom
1 program
IH OxytocinPHASE_11 trial
Active Trials
NCT02999100Terminated31Est. Mar 2019
CSL Behring
CSL BehringIL - Bradley
1 program
fibrinogen concentratePHASE_1_21 trial
Active Trials
NCT02528708Withdrawn0Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CiplaMisoprostol
CSL Behringfibrinogen concentrate
Grand MedicalTampostat
Ferring PharmaceuticalsCarbetocin
GSKIH Oxytocin
KoKoKOKO Device
Angel PharmaceuticalsFibrinogen Concentrate Human
LundbeckSafe Delivery smartphone application

Clinical Trials (8)

Total enrollment: 5,012 patients across 8 trials

NCT01373359CiplaMisoprostol

Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin

Start: Mar 2007Est. completion: Jan 2008652 patients
Phase 3Completed
NCT02528708CSL Behringfibrinogen concentrate

A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)

Start: Jan 2021Est. completion: Dec 20210
Phase 1/2Withdrawn

Tampostat for Management of Postpartum Hemorrhage

Start: Apr 2015Est. completion: Dec 2016344 patients
Phase 1/2Terminated

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

Start: May 2023Est. completion: Sep 202340 patients
Phase 1Completed
NCT02999100GSKIH Oxytocin

Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women

Start: Nov 2016Est. completion: Mar 201931 patients
Phase 1Terminated
NCT06452355KoKoKOKO Device

Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage

Start: Aug 2024Est. completion: Aug 202672 patients
N/ARecruiting
NCT03784794Angel PharmaceuticalsFibrinogen Concentrate Human

Patient Blood Management for Massive Obstetric Hemorrhage

Start: Nov 2018Est. completion: Dec 2020100 patients
N/ACompleted
NCT02185625LundbeckSafe Delivery smartphone application

Reduction of Adverse Pregnancy Outcomes With a Smartphone Application in Ghana

Start: Jul 2014Est. completion: Sep 20143,773 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 5,012 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.